LTRN vs. IOBT, GLTO, LFVN, ABEO, CNTB, ADAG, PIRS, ALZN, GANX, and MYNZ
Should you be buying Lantern Pharma stock or one of its competitors? The main competitors of Lantern Pharma include IO Biotech (IOBT), Galecto (GLTO), LifeVantage (LFVN), Abeona Therapeutics (ABEO), Connect Biopharma (CNTB), Adagene (ADAG), Pieris Pharmaceuticals (PIRS), Alzamend Neuro (ALZN), Gain Therapeutics (GANX), and Mainz Biomed (MYNZ). These companies are all part of the "pharmaceutical preparations" industry.
Lantern Pharma vs.
Lantern Pharma (NASDAQ:LTRN) and IO Biotech (NASDAQ:IOBT) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, community ranking, risk, media sentiment and profitability.
Lantern Pharma has a beta of 0.64, suggesting that its stock price is 36% less volatile than the S&P 500. Comparatively, IO Biotech has a beta of -0.69, suggesting that its stock price is 169% less volatile than the S&P 500.
Lantern Pharma received 4 more outperform votes than IO Biotech when rated by MarketBeat users.
In the previous week, IO Biotech had 2 more articles in the media than Lantern Pharma. MarketBeat recorded 2 mentions for IO Biotech and 0 mentions for Lantern Pharma. Lantern Pharma's average media sentiment score of 0.00 beat IO Biotech's score of -0.83 indicating that Lantern Pharma is being referred to more favorably in the media.
21.6% of Lantern Pharma shares are held by institutional investors. Comparatively, 53.2% of IO Biotech shares are held by institutional investors. 6.9% of Lantern Pharma shares are held by insiders. Comparatively, 3.5% of IO Biotech shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Lantern Pharma's return on equity of -24.53% beat IO Biotech's return on equity.
Lantern Pharma currently has a consensus target price of $11.00, indicating a potential upside of 108.33%. IO Biotech has a consensus target price of $11.00, indicating a potential upside of 436.59%. Given IO Biotech's stronger consensus rating and higher possible upside, analysts clearly believe IO Biotech is more favorable than Lantern Pharma.
Lantern Pharma is trading at a lower price-to-earnings ratio than IO Biotech, indicating that it is currently the more affordable of the two stocks.
Summary
Lantern Pharma beats IO Biotech on 8 of the 14 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding LTRN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Lantern Pharma Competitors List
Related Companies and Tools